Forward Looking Statements
Certain matters discussed on the Site are “forward-looking statements.” Metaclipse Biopharma may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, Metaclipse Biopharma’s statements regarding trends and potential future results are examples of such forward-looking statements.
The forward-looking statements include risks and uncertainties, and include, but are not limited to, the efficacy, safety, tolerability and cost of Metaclipse’s manufacturing processes; the success, timing, and cost of Metaclipse’s anticipated clinical trials for its current product candidates, including statements regarding the timing of initiation and completion of the trials; statements with respect to the preliminary clinical results from ongoing clinical studies, which may not be reflected in the final analyses of these studies; whether results obtained in Metaclipse’s ongoing clinical trials, such as the studies and trials referred to on this Site, will be indicative of results obtained in future clinical trials; the timing of and Metaclipse’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, its product candidates; the strength of Metaclipse’s product pipeline; the successful implementation of Metaclipse’s research and development programs and collaborations; the success of Metaclipse’s license or development agreements; the acceptance by the market of Metaclipse’s product candidates, if approved; and other factors, including general economic conditions and regulatory developments, not within Metaclipse’s control.
The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of access to the Site, and Metaclipse undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.
Disclaimer
Membrex™ and VaxRex™ are investigational therapies and have not been approved for any indication by the Food and Drug Administration (FDA) or any other regulatory agency. The safety and efficacy of these therapies have not been determined.